Strides Pharma Science · NSE: STAR · BSE: 532531

Q4 FY20 results · Jan–Mar 2020

Strides Pharma Science reported revenue from operations of ₹618.64 crore (down 26.3% from Q4 FY19) and net loss of ₹206.57 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	618.64	839.70	−26.3%	732.44	−15.5%
Other income	17.65	14.59	+21.0%	12.22	+44.4%
Total income	636.29	854.29	−25.5%	744.66	−14.6%
Profit before share of associates & JVs and tax	(173.08)	76.01	Turned loss	127.02	Turned loss
Share of profit/(loss) of associates & JVs	(44.78)	(21.15)		(23.39)
Net profit for the period	(206.57)	44.70	Turned loss	92.33	Turned loss
Attributable to shareholders of the company	(203.93)	47.51	Turned loss	93.89	Turned loss
EPS, basic (₹)	(22.77)	5.31	Turned loss	10.48	Turned loss
Net margin (%)	-33.4	5.3		12.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	441.74	434.56	+1.7%	364.47	+21.2%
Other income	27.26	56.41	−51.7%	17.62	+54.7%
Total income	469.00	490.97	−4.5%	382.09	+22.7%
Profit before tax	47.77	94.90	−49.7%	15.53	+207.6%
Net profit for the period	26.37	98.82	−73.3%	13.65	+93.2%
EPS, basic (₹)	2.94	11.04	−73.4%	1.52	+93.4%
Net margin (%)	6.0	22.7		3.7

Consolidated

Filed with BSE: 21 May 2020, 13:42 IST
Board meeting: 20 May 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 21 May 2020, 13:42 IST
Board meeting: 20 May 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE